Close Menu

NEW YORK – Sanofi and Regeneron announced on Monday that they were stopping a Phase III trial of PD-1 inhibitor cemiplimab (Libtayo) early after it met its primary endpoint of improving overall survival over platinum doublet chemotherapy in first-line, PD-L1-positive advanced non-small cell lung cancer patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.